Left Main Coronary Artery Stenosis Clinical Trial
— LEMONOfficial title:
LEft Main Oct Guided iNterventions
Verified date | January 2020 |
Source | Institut Mutualiste Montsouris |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
LEMON aim is to evaluate the feasibility, efficiency and security of a standardized Optical Coherence Tomography (OCT) - guided protocol for completion and optimization of Left Main (LM) Percutaneous Coronary Intervention (PCI).
Status | Completed |
Enrollment | 71 |
Est. completion date | February 1, 2019 |
Est. primary completion date | January 28, 2019 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - age >18 - stable or non-stable distal Left Main lesion (with or without previous Coronary Artery Bypass Graft), involving or not Left Anterior Descending and Coronary Circumflex ostias and requiring Percutaneous Coronary Intervention with a one or two stents strategy - stable or non-stable ostial Left Anterior Descending and/or Coronary Circumflex lesion requiring Percutaneous Coronary Intervention with involvement of distal Left Main - SYNTAX angiographic score <23 - informed consent Exclusion Criteria: - ostial Left Main lesion - on-going acute STEMI - on-going cardiogenic shock - severe chronic renal failure (Cr Cl <30 ml/min/m2) - anticipated technical contra-indication to OCT (highly calcified lesions, severe proximal tortuosity) |
Country | Name | City | State |
---|---|---|---|
France | Chu Besancon | Besancon | |
France | Chu Bordeaux | Bordeaux | |
France | Clinique Saint Augustin | Bordeaux | |
France | Hôpital privé Saint Martin | Caen | |
France | Chu Clermont Ferrand | Clermont Ferrand | |
France | Ch Chartres | Le Coudray | |
France | Institut hospitalier Jacques Cartier | Massy | |
France | Ch Annecy Genevois | Metz-Tessy | |
France | CHU Nîmes | Nîmes | |
France | Institut Mutualiste Montsouris | Paris | |
France | Clinique Saint Hilaire | Rouen |
Lead Sponsor | Collaborator |
---|---|
Institut Mutualiste Montsouris |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | success of the OCT procedure | score Thrombolysis In Myocardial Infarction (TIMI) equal to 3 in all vessels, 50% residual stenosis in the various angiography segments, adequate expansion according to minimum intra stent area > 80% of the luminal area of the reference segment on Main Vessel and Main Branch. | Post PCI / Immediate | |
Secondary | incidence of major adverse cardiovascular events | death, cardiovascular death, stent thrombosis, target vessel revascularization | 30 days post PCI | |
Secondary | rate of appropriate wire position | percentage of appropriate wire position in adequate stent cell before side branch ostium dilation. | 30 days post PCI | |
Secondary | rate of appropriate stent expansion according to DOCTORS and ILUMIEN-III criteria. | percentage of stent expansion according to DOCTORS and ILUMIEN-III | 30 days post PCI |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02765646 -
eTryton Left Main Registry Tryton Side Branch Stent® Tmt of Denovo CAD in LM and CFX Arteries
|
||
Active, not recruiting |
NCT04111770 -
The OPTIMAL Randomized Controlled Trial
|
N/A | |
Not yet recruiting |
NCT05650411 -
P2Y12 Inhibitor-based Single Antiplatelet Therapy After a Short DAPT vs. Conventional DAPT Following PCI With a Polymer-free Drug-coated Stent for Unprotected Left Main Coronary Artery Disease (ULTRA-LM)
|
N/A | |
Active, not recruiting |
NCT03767621 -
Concordance Between FFR and iFR for the Assessment of Intermediate Lesions in the Left Main Coronary Artery. A Prospective Validation of a Default Value for iFR
|